IP Library › Granted Patent US 10,548,905
Granted Patent B2
US 10,548,905 · App. 15/378,004 · Granted Feb 4, 2020

Amorphous onapristone compositions and methods of making the same

Inventors: Harry G. Brittain (Milford, NJ); Stefan Proniuk (Austin, TX)
Assignee: CONTEXT BIOPHARMA INC.
A61K31/575A61K9/1635A61K9/1641A61K9/1682C07J41/0055
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,548,905
App. No.
15/378,004
Granted
Feb 4, 2020
Kind
B2
Abstract

Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.

Claims (12)

1. A method of making a stable amorphous onapristone precipitate comprising:

mixing onapristone and water to form an onapristone slurry;

mixing at least one equivalent of an acid solution with the onapristone slurry to form a onapristone solution, wherein the pH of the onapristone solution mixed with the acid is about 1 or below;

mixing at least one equivalent of a base to the onapristone solution to form the stable amorphous onapristone precipitate, wherein the pH of the onapristone solution mixed with the base is about 10 or above;

isolating the stable amorphous onapristone precipitate by filtration; and

drying the stable amorphous onapristone precipitate, wherein the dried stable amorphous onapristone precipitate remains amorphous for at least 25 weeks.

2. The method of claim 1 , wherein the acid solution comprises an acid selected from the group consisting of hydrochloric acid, nitric acid, and sulfuric acid.

3. The method of claim 1 , wherein the base is selected from the group consisting of sodium hydroxide, potassium hydroxide, and ammonium hydroxide.

4. The method of claim 1 , wherein the amorphous onapristone precipitate remains amorphous for at least 16.5 months.

5. The method of claim 1 , wherein the amorphous onapristone precipitate does not contain crystalline onapristone.

6. The method of claim 1 , wherein the XPRD pattern of the amorphous onapristone precipitate does not contain any sharp peaks.

7. The method of claim 1 , further comprising storing the dried stable amorphous under ambient conditions for at least 25 weeks, wherein the onapristone precipitate remains amorphous for the at least 25 weeks.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 11, 2021
From: LEHR, SETH
To: CONTEXT BIOPHARMA, INC.
Reel/Frame 055560/0750 →
SECURITY INTEREST Recorded Apr 2, 2020
From: CONTEXT BIOPHARMA, INC.
To: LEHR, SETH
Reel/Frame 052293/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2018
From: ARNO THERAPEUTICS, INC.
To: CONTEXT BIOPHARMA INC.
Reel/Frame 044769/0620 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2017
From: BRITTAIN, HARRY G.; PRONIUK, STEFAN
To: ARNO THERAPEUTICS, INC.
Reel/Frame 044285/0296 →
Continuity (2)
Provisional Application 62267540 · Dec 15, 2015
Related Publication 20170182065A1 · Jun 29, 2017